Posted by Michael Wonder on 08 Oct 2019
Novartis receives FDA approval for Beovu, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
8 October 2019 - In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients.
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD).
Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
